deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03206970

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Sponsor: BeiGene

Conditions Refractory Mantle Cell Lymphoma Relapsed Mantle Cell Lymphoma
Interventions Zanubrutinib
Updated 16 times since 2017 Last updated: Oct 23, 2024 Started: Mar 2, 2017 Primary completion: Feb 15, 2019 Completion: Sep 8, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Refractory Mantle Cell Lymphoma and Relapsed Mantle Cell Lymphoma and is currently completed. BeiGene leads this study, which shows 16 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Aug 2017 – ~Apr 2018 · 8 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Jun 2020 · 4 months · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Dec 2021 · 10 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – present · 21 months · monthly snapshot

Change History

16 versions recorded

  1. Nov 2024 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Nov 2024 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Feb 2021 — Dec 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 11 earlier versions

  1. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Jun 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE2

  4. Feb 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE2

  5. Dec 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Oct 2019 — Dec 2019 [monthly]

    Active Not Recruiting PHASE2

  7. Sep 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE2

  8. Jun 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE2

  9. Jun 2018 — Jun 2019 [monthly]

    Active Not Recruiting PHASE2

  10. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  11. Aug 2017 — Apr 2018 [monthly]

    Recruiting PHASE2

    First recorded

Mar 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • BeiGene
Data source: BeiGene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changchun, China , Chengdu, China , Fuzhou, China , Guangzhou, China , Hangzhou, China , Nanjing, China , Shanghai, China , Tianjin, China , Wuhan, China and 1 more location